EU Court Backs Astra Antitrust Fine Over Patent Abuse

Law360, New York (July 1, 2010, 1:40 PM EDT) -- A European court affirmed on Thursday a 2005 European Commission decision that AstraZeneca PLC abused its market dominance and the patent system in order to block generic competitors for its blockbuster ulcer drug Losec, but trimmed €7.5 million ($9.4 million) from the drugmaker's fine for hindering parallel imports.

The General Court of the European Union upheld the bulk of the European Commission's decision and €60 million fine against the Anglo-Swedish company, agreeing that AstraZeneca had misled national patent offices in order to extend its patent protections...
To view the full article, register now.